News Archives - Page 82 of 88

WednesdayJul 13, 2022 2:38 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Nearing Start Date for Its Human Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the pending start of its upcoming human nicotine study NIC-H22-1. Through the study, Lexaria expects to evidence that processing purified nicotine with its patented drug delivery technology, DehydraTECH(TM), leads to enhanced oral-tissue absorption and reduced negative experiences. NIC-H22-1, a minimum 36-person human pharmacokinetic (“PK”) randomized, double blinded, cross-over study, will compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the U.S. such as ON! and Zyn. The primary objective of the study is data collection from blood samples that will evidence…

WednesdayJul 13, 2022 2:21 pm

TinyGemsBreaks – Standard Lithium Ltd (TSX.V: SLI) (NYSE American: SLI) (FRA: S5L) Releases Update on Key Developments

Standard Lithium (TSX.V: SLI) (NYSE American: SLI) (FRA: S5L), an innovative technology and lithium project-development company, is reporting on recent corporate and project developments. Highlights of the update include additions to SLI management, a master service agreement (“MSA”) with Telescope Innovations (“TELI”), the progress of a DFS/FEED study award and increased shareholdings by senior management. Specifically, SLI named new positions and members to its management team, including Jason Tielker as vice president of project delivery and Angus Remfry as director of project delivery. In addition, the company is reviewing Pre-FEED deliverables related to its first commercial plant with the anticipation…

TuesdayJul 12, 2022 3:22 pm

TinyGemsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Phase 1/2a Clinical Trial Through Clinilabs Begins Enrollment

Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced commencement of enrollment in a phase 1/2a clinical trial of CYB003. Being developed by Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” CYB003 is the first novel psilocybin analog to be evaluated in phase 1/2a development for the treatment of major depressive disorder (“MDD”). “Clinilabs is honored to be working with Cybin, an innovator in the development of novel psychedelic therapeutics, to conduct its first-in-human clinical trial of CYB003,” said…

TuesdayJul 12, 2022 2:23 pm

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Upgrades EDI to Include Location Sharing, Shipment Status Improvements

Freight Technologies (NASDAQ: FRGT), a technology company developing solutions to optimize and automate the supply chain process and providing a platform for B2B cross-border shipping in the NAFTA region, announced that it has upgraded its electronic data interchange (“EDI”). The upgraded EDI now features the ability to enable location sharing and shipment status changes. “To help increase Fr8App large shippers’ efficiency and the stickiness of our application, we continue to improve our EDI, which increases notification speed and reduces costs with our agile, paperless electronic exchange of data,” said Fr8Tech and Fr8App CEO Javier Selgas in the press release. “Recently,…

MondayJul 11, 2022 2:05 pm

TinyGemsBreaks – Knightscope Inc. (NASDAQ: KSCP) Secures New Contract from Large Real Estate Investment Trust (REIT)

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, announced its receipt of another new contract for autonomous security robot (ASR) services. The announcement reads, “One of the largest U.S. real estate investment trusts (REIT) signed an agreement for Knightscope’s K5 ASR to patrol one of its open-air, mixed-use shopping centers in southern Florida. As of 2022, the client owns and operates more than 500 shopping centers and mixed-use assets in the United States representing more than 93 million square feet of leasable space. It considers its Florida property to be a ‘lifestyle…

MondayJul 11, 2022 11:59 am

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Enters Agreement Putting Cargo Van Program ‘Front and Center for Last Mile Delivery Opportunities’

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced its entry into a binding agreement with DelPack Logistics LLC (“DPL”), an Amazon Delivery Service Partner, for DPL to purchase up to 600 Mullen Class 2 EV cargo vans over the next 18 months. The vans will be fully homologated for the United States and equipped with all airbags as required by U.S. standards and a cabin comfort package, including adjustable seats, cup holders, an infotainment system, and comfortable passenger seat. In addition, the EV cargo vans will carry a minimum of an 80 kilowatt per hour battery…

MondayJul 11, 2022 11:42 am

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study Expected to Accelerate Clinical Development Path of CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has completed the acquisition of a phase 1 N,N-dimethyltryptamine (“DMT”) study from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1). The DMT study, which is the largest to date, is expected to accelerate the clinical development path of Cybin’s proprietary deuterated DMT molecule for the potential treatment of anxiety disorders, CYB004, by approximately nine months. “With the closing of this transaction, we are well on our way to advancing CYB004 through phase 1…

MondayJul 11, 2022 11:21 am

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Names Former Amazon, Boeing Exec as CFO

Flora Growth’s (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, has announced a new chief financial officer. Former Amazon and Boeing official Elshad Garayev has accepted the new position and will be joining the FLTC team on the business day following the date on which the company files its mid-year financial results with the Securities and Exchange Commission. Garayev has more than two decades of financial leadership experience, and has worked at Amazon, Boeing, BP and RPK Capital. In his new role, he will focus on FLGTC growth initiatives as well as financial…

FridayJul 08, 2022 12:52 pm

TinyGemsBreaks – Knightscope Inc. (NASDAQ: KSCP) Secures New Contract with Storage Facility in Napa Valley

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, announced its entry into a new agreement with a storage facility in Napa, California. The announcement reads, “The use of storage facilities has increased 65% over the past 15 years. While such facilities are generally safe, they often experience break-ins leaving personal possessions and commercially stored items at risk. Knightscope’s K5 Autonomous Security Robot (‘ASR’) will patrol the storage facility to further enhance the protection offered to tenants that choose to store their belongings with them. Prospective renters are encouraged to do their due…

FridayJul 08, 2022 10:57 am

TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Moves One Step Closer to In-Human Trials with Completion of Preclinical Toxicity Study

Aditxt Inc. (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, has successfully completed a toxicology study evaluating Adimune(TM), its proprietary therapeutic program. The study indicates the safety profile of ADI(TM)-100, ADTX’s immunotherapeutic technology drug, which is designed to treat the rejection of transplanted organs, skin allografting, autoimmune diseases and allergies. Calling the study results “promising,” the company noted that those results will provide vital supporting evidence when Aditxt moves forward with an investigational new drug (“IND”) application with the regulatory agencies. According to the announcement, ADI-100 is made of two DNA…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Breaks Categories: News